Myxedema coma diagnostic criteria

Jump to navigation Jump to search

Myxedema coma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Myxedema coma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myxedema coma diagnostic criteria On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Myxedema coma diagnostic criteria

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myxedema coma diagnostic criteria

CDC on Myxedema coma diagnostic criteria

Myxedema coma diagnostic criteria in the news

Blogs on Myxedema coma diagnostic criteria

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Myxedema coma diagnostic criteria

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]Sophia Saad, Associate Editor - WikiDoc [3]

Myxedema coma diagnostic criteria

Diagnosis of myxedema coma (decompensated hypothyroidism) is primarily clinical. Treatment should be initiated on clinical suspicion without waiting for laboratory confirmation or formal scoring.[1][2][3]

Classic clinical features that raise suspicion include:

  • Altered mental status (lethargy, obtundation, stupor, or coma)
  • Hypothermia (or absence of fever in the setting of infection)
  • Presence of a precipitating event (infection, cold exposure, drugs, nonadherence, surgery, etc.)

These features alone are not sufficiently specific; a structured scoring system improves diagnostic consistency.[1]

Popoveniuc diagnostic scoring system

The most widely referenced diagnostic tool is the Popoveniuc scoring system (2014), which assigns points across multiple organ-system domains. It derives from a small retrospective cohort; an alternative objective instrument (Chiong/Mariash, 2015; ~80% sensitivity and specificity) uses different variables, and no prospectively validated, universally adopted criteria yet exist.[1][4]

Interpretation thresholds are:

  • Score ≥60: highly suggestive / diagnostic of myxedema coma
  • Score 45–59: suggestive of risk for myxedema coma
  • Score <45: unlikely to represent myxedema coma

In the derivation cohort, a score ≥60 had 100% sensitivity and 85.7% specificity (AUC 0.88). Clinical judgment remains essential; the score is an aid, not a rigid rule.[1][2]

Diagnostic Scoring System for Myxedema Coma (Popoveniuc et al., 2014)
Component Variable Points
Thermoregulatory dysfunction Temperature >35 °C 0
32–35 °C 10
<32 °C 20
Central nervous system effects Somnolent / lethargic 10
Obtunded 15
Stupor 20
Coma / seizures 30
Cardiovascular Bradycardia absent 0
Heart rate 50–59 bpm 10
Heart rate 40–49 bpm 20
ECG changes (QT prolongation, low voltage, bundle-branch block, nonspecific ST-T changes, heart block) 10
Pericardial effusion 10
Cardiomegaly 15
Gastrointestinal Anorexia / abdominal pain / constipation 5
Decreased intestinal motility 15
Paralytic ileus 20
Precipitating event Absent 0
Present 10
Metabolic disturbances Hyponatremia 10
Hypoglycemia 10
Hypoxemia 10
Hypercarbia 10
Decrease in GFR 10
Others Pleural effusion 10
Pulmonary edema 15
Hypotension 20

Notes on scoring

  • ECG changes include QT prolongation, low-voltage complexes, bundle-branch blocks, nonspecific ST-T changes, or heart blocks.
  • A total score ≥60 is highly suggestive/diagnostic of myxedema coma.
  • A score of 45–59 indicates elevated risk and should prompt strong consideration of empiric therapy.
  • Scores <45 make the diagnosis unlikely.
  • Concurrent assessment of adrenal function (serum cortisol) is recommended because relative adrenal insufficiency frequently coexists and influences immediate management sequencing (empiric glucocorticoid before thyroid hormone).[5][2]

Contrast with thyroid-storm scoring

The Burch–Wartofsky Point Scale is designed for thyroid storm and must not be applied to myxedema coma. The two syndromes are opposite ends of the thyroid-function spectrum and use entirely different diagnostic instruments.[1]

Clinical diagnosis versus laboratory confirmation

Thyroid function tests (elevated TSH with low free T4 in primary hypothyroidism; low or inappropriately normal TSH with low free T4 in central hypothyroidism) support the diagnosis but do not define severity. TSH magnitude correlates poorly with clinical severity. Treatment must not be delayed pending laboratory results or formal scoring.[3][5]

Differential diagnosis

Key mimics include nonthyroidal illness (euthyroid sick) syndrome—low T3 (and in severe cases low T4) with normal/low TSH and high reverse T3, best distinguished by TSH—as well as environmental hypothermia, sepsis, drug/toxin-induced CNS depression, hypoglycemia, hypercapnic respiratory failure, and adrenal crisis. Assay interference (biotin, macro-TSH, heparin) should be suspected when results do not fit the clinical picture.[6][7]

References

  1. 1.0 1.1 1.2 1.3 1.4 Popoveniuc G, Chandra T, Sud A, et al. A diagnostic scoring system for myxedema coma. Endocr Pract. 2014;20(8):808-817.
  2. 2.0 2.1 2.2 Cruz-Flores S. Neurological Complications of Endocrine Emergencies. Curr Neurol Neurosci Rep. 2021;21(5):21.
  3. 3.0 3.1 Chaker L, Papaleontiou M. Hypothyroidism. JAMA. 2025.
  4. Chiong YV, et al. Transl Res. 2015.
  5. 5.0 5.1 Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the Treatment of Hypothyroidism. Thyroid. 2014;24(12):1670-1751.
  6. Taylor PN, et al. Hypothyroidism. Lancet. 2024;404(10460):1347-1364.
  7. Melmed S, et al. J Clin Endocrinol Metab. 1982.